{"id":639615,"date":"2023-02-22T15:12:02","date_gmt":"2023-02-22T15:12:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=639615"},"modified":"2023-02-22T15:12:02","modified_gmt":"2023-02-22T15:12:02","slug":"fucosidosis-market-analysis-of-epidemiology-pipeline-therapies-and-key-companies-working-in-the-market","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/fucosidosis-market-analysis-of-epidemiology-pipeline-therapies-and-key-companies-working-in-the-market_639615.html","title":{"rendered":"Fucosidosis Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the Market"},"content":{"rendered":"
\n
\"Fucosidosis<\/a><\/div>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
DelveInsight’s “Fucosidosis Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Fucosidosis, historical and forecasted epidemiology as well as the Fucosidosis market trends in the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.<\/div>\n

DelveInsight’s “Fucosidosis Market Insights, Epidemiology, and Market Forecast-2032<\/a><\/strong>” report delivers an in-depth understanding of the Fucosidosis, historical and forecasted epidemiology as well as the Fucosidosis market trends in the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.<\/p>\n

The Fucosidosis market report provides current treatment practices, emerging drugs, Fucosidosis market share of the individual therapies, and current and forecasted Fucosidosis market size from 2019 to 2032 segmented by seven major markets. The Report also covers current Fucosidosis treatment practices\/algorithms, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities. It assesses the underlying potential of the market.<\/p>\n

\"\"<\/p>\n

Fucosidosis Overview<\/strong><\/p>\n

Fucosidosis is a rare genetic disorder characterized by a deficiency of the enzyme alpha-L-fucosidase, which is required to break down (metabolize) certain complex compounds (e.g., fucose-containing glycolipids or fucose-containing glycoproteins). Fucose is a type of sugar required by the body to perform certain functions (essential sugar). The inability to breakdown fucose-containing compounds results in their accumulation in various tissues in the body. Fucosidosis results in progressive neurological deterioration, skin abnormalities, growth retardation, skeletal disease, and coarsening of facial features. The symptoms and severity of fucosidosis are highly variable and the disorder represents a disease spectrum in which individuals with mild cases have been known to live into the third or fourth decades. Individuals with severe cases of fucosidosis can develop life-threatening complications early in childhood.<\/p>\n

Fucosidosis Epidemiology Insights:<\/strong><\/p>\n